{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:54:12Z","timestamp":1772117652257,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008980","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T00:00:00Z","timestamp":1375920000000}}],"reference-count":49,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008980.pub2","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T08:15:43Z","timestamp":1375949743000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation"],"prefix":"10.1002","author":[{"given":"Karsten MH","family":"Bruins Slot","sequence":"first","affiliation":[{"name":"Oslo University Hospital; Department of Internal Medicine; Oslo Norway NO-0407"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eivind","family":"Berge","sequence":"additional","affiliation":[{"name":"Oslo University Hospital; Department of Internal Medicine; Oslo Norway NO-0407"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,8]]},"reference":[{"key":"10.1002\/14651858.CD008980.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"The Amadeus Investigators","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","article-title":"Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation","volume":"75","author":"Ogawa","year":"2011","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH10-07-0451","article-title":"Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation","volume":"105","author":"Chung","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"issue":"20","key":"10.1002\/14651858.CD008980.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/eurheartj\/eht\/039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)","volume":"34","author":"Connoly","year":"2013","journal-title":"European Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD008980.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation","volume":"76","author":"Hori","year":"2012","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0008|cit8","first-page":"173","article-title":"Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a phase II study","volume":"31 Suppl 1","author":"Turpie","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0009|cit9","first-page":"748","article-title":"Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2)","volume":"9 Suppl 2","author":"Lip","year":"2011","journal-title":"Journal of Thrombosis and Haemostatis"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008980.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2165\/11595540-000000000-00000","article-title":"Edoxaban: a new oral direct factor xa inhibitor","volume":"71","author":"Camm","year":"2011","journal-title":"Drugs"},{"issue":"19","key":"10.1002\/14651858.CD008980.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD008980.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008980.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ecp.09.55","article-title":"Idraparinux and idrabioparinux","volume":"3","author":"Harenberg","year":"2010","journal-title":"Expert Review of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008980.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.10-3270","article-title":"Bleeding risk in patients with atrial fibrillation: the AMADEUS study","volume":"140","author":"Lane","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD008980.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD008980.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2217\/fca.11.28","article-title":"Edoxaban: pharmacological principles, preclinical and early-phase clinical testing","volume":"7","author":"Partida","year":"2011","journal-title":"Future Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008980.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"ROCKET AF Study Investigators","year":"2010","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0019|cit19","unstructured":"Evaluation of weekly subcutaneous biotinylated idraparinux versus oral adjusted-dose warfarin to prevent stroke and systemic thromboembolic events in patients with atrial fibrillation (BOREALIS-AF) ClinicalTrials.gov 2007"},{"issue":"4","key":"10.1002\/14651858.CD008980.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)","volume":"160","author":"Ruff","year":"2010","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.177031","article-title":"Guidelines for the management of patients with atrial fibrillation","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1368-5031.2006.00790.x","article-title":"Patterns of use of antithrombotic therapy and quality of anticoagulation monitoring among patients with non-valvular atrial fibrillation in clinical practice","volume":"60","author":"Boulanger","year":"2006","journal-title":"International Journal of Clinical Practice"},{"issue":"22","key":"10.1002\/14651858.CD008980.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0024|cit24","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCULATIONAHA.107.695163","article-title":"Challenges of establishing new antithrombotic therapies in atrial fibrillation","volume":"116","author":"Connolly","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of International Normalized Ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care. Meta-analysis in Context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","article-title":"New anticoagulants","volume":"121","author":"Eikelboom","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation","volume":"31","author":"The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Camm AJ Lip GYH De Caterina R Savelieva I Atar D Hohnloser SH 2012 focused update of the ESC Guidelines for the management of atrial fibrillation www.escardio.org\/guidelines-surveys\/esc-guidelines\/Pages\/atrial-fibrillation.aspx","DOI":"10.1007\/978-1-908517-31-9_17"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/eurheartj\/ehm358","article-title":"Outcome parameters for trials in atrial \ufb01brillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)","volume":"28","author":"Kirchhof","year":"2007","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham heart study","volume":"110","author":"Lloyd-Jones","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","article-title":"Contribution of atrial fibrillation to incidence and outcome of ischemic stroke. Results from a population study","volume":"36","author":"Marini","year":"2005","journal-title":"Stroke"},{"issue":"3","key":"10.1002\/14651858.CD008980.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projection for future prevalence","volume":"114","author":"Miyasaki","year":"2006","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-60761-803-4_6","article-title":"Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban","volume-title":"Anticoagulants, Antiplatelets, and Thrombolytics","author":"Mousa","year":"2010"},{"issue":"5","key":"10.1002\/14651858.CD008980.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0043|cit43","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/bmj.314.7093.1529","article-title":"Population-based study of the use of anticoagulants among patients with atrial fibrillation in the community","volume":"314","author":"Sudlow","year":"1997","journal-title":"BMJ"},{"issue":"9745","key":"10.1002\/14651858.CD008980.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"18","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0046|cit46","unstructured":"Wallentin L Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation http:\/\/www.escardio.org\/congresses\/esc-2011\/congress-reports\/Documents\/28-8-CTU\/ARISTOTLE-presenter-Wallentin-slides.pdf 2011"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/01.CIR.0000083722.42033.0A","article-title":"Increasing trends in hospitalisation for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention","volume":"108","author":"Wattigney","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008980.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008980.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008980.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:26:14Z","timestamp":1628533574000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008980.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Stroke Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,8]]},"references-count":49,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008980.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718061866.793484592","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,8]]}}}